Compare Citius Pharmaceuticals Inc (CTXR) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Macy's Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while Macy's Inc trades at $22.88 (market cap $5.95B). The key difference: Macy's Inc is far larger — about 431.5× Citius Pharmaceuticals Inc's market cap, and Macy's Inc pays a 3.36% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Macy's Inc for 58 Days on average.
| CTXR | M | |
|---|---|---|
Market Cap | $13.79M | $5.95B |
Volume | 156,684 | 11,329,747 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $26.21 |
52-Week Low | $0.48 | $16.51 |
Typical Hold Time | 16 Days | 58 Days |
Enterprise Value | $3.96M | $9.75B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
Macy's stock trades at $22.79, up 1.47% with a bullish technical signal and strong valuation metrics including a P/E of 8.35 and P/S of 0.27. The company has beaten earnings estimates for three consecutive quarters and maintains a 3.5% dividend yield. Recent 'Bold New Chapter' strategy initiatives are showing traction with improved sales and operational metrics.
The stock offers attractive value with upside to the $24.25 consensus target, though Q3 earnings risk and retail sector headwinds remain concerns. Positive cash flow generation and debt reduction support the dividend, while digital transformation efforts provide growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
